Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx

• Verfasst von: Hauswald, Henrik [VerfasserIn]
• Verfasst von: Jensen, Alexandra [VerfasserIn]
• Verfasst von: Krauß, Jürgen [VerfasserIn]
• Verfasst von: Haselmann, Renate [VerfasserIn]
• Verfasst von: Lossner, Karen [VerfasserIn]
• Verfasst von: Münter, Marc [VerfasserIn]
• Verfasst von: Debus, Jürgen [VerfasserIn]
• Titel: Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx
• Verf.angabe: H. Hauswald, A. D. Jensen, J. Krauss, R. Haselmann, K. Lossner, S. Hartmann, C. Windemuth-Kieselbach, M. W. Münter, J. Debus
• E-Jahr: 2018
• Jahr: November 2018
• Umfang: 10 S.
• Fussnoten: Gesehen am 20.12.2018
• Titel Quelle: Enthalten in: Clinical and translational radiation oncology
• Ort Quelle: Amsterdam : Elsevier, 2016
• Jahr Quelle: 2018
• Band/Heft Quelle: 13(2018), Seite 64-73
• ISSN Quelle: 2405-6308
• DOI: doi:10.1016/j.ctro.2018.09.005
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Carbon ion therapy
• Sach-SW: Cetuximab
• Sach-SW: Head and neck cancer
• Sach-SW: LAHNC
• Sach-SW: Particle therapy
• Sach-SW: SCCHN
• K10plus-PPN: 1585802867
• K10plus-PPN:
  Universitätsbibliothek
• Lokale URL UB: Zum Volltext

Abstract

Purpose: This phase II trial was designed to evaluate efficacy and safety of a highly intensified therapy in locally advanced squamous cell carcinoma of the oro-, hypopharynx and larynx. Methods: In this prospective, mono-centric, open-label, non-randomized phase II trial the single treatment arm consisted of a combined induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil, followed by bioradiation with the monoclonal antibody cetuximab, carbon ion boost (24Gy(RBE) in 8 fractions) and IMRT (50Gy in 25 fractions). The trial was closed early due to slow accrual. Results: Eight patients (median age 52.5years) were enrolled into the trial. The median follow-up was 13months and the 12-months locoregional tumor control, progression-free survival and overall survival rates were 100.0% each. Complete remission was achieved in 7 patients. The most commonly late radiation adverse event was xerostomia (85.7% at 12months). Five serious adverse events with recovery were documented in 4 patients: mucositis grade 3 (n=2), decreased lymphocyte count grade 4, febrile neutropenia grade 4 and hypersensitivity grade 3 to cetuximab (n=1 each). Most symptom scales had their worst value at the last treatment day and recovered until the 4th follow-up visit. Conclusion: The study treatment was tolerable and promising. Reduced quality of life recovered for most aspects until the last follow-up visit.